LAKEWOOD, Colo.– Vivo Infusion, a nationally recognized provider of accessible and affordable ambulatory infusion services, announced today it has acquired Infusion Associates (“the Company”), an industry leader in ambulatory infusion services with centers in Michigan, Minnesota, Ohio and Wisconsin. With this acquisition, Vivo Infusion will manage nearly 80 ambulatory infusion centers across 15 states. Financial terms of the transaction were not disclosed.
Founded in 2001, Infusion Associates has grown across the Midwest through both de novo center openings and strategic acquisitions. The Company has a unique operating model including both physician partnerships and a clinical trials division which enhance its offerings to patients, payors and pharma partners. Combining clinical expertise and a deep understanding of patient care and experience, Infusion Associates has built a truly unique ambulatory infusion offering for several previously underserved markets. Following the transaction, Vivo anticipates continued growth across the Midwest from additional de novo center build-outs.
“We are thrilled to welcome the Infusion Associates team to the Vivo family,” said Chris Reef, Chief Executive Officer of Vivo Infusion. “Infusion Associates brings several unique capabilities to Vivo’s growing business which will continue to strengthen our relationships with our patients, payors and pharma partners. We are delighted to partner with the entire team.”
“I am excited to join the Vivo mission. We look forward to bringing these two great companies together and serving more lives by providing an industry-leading patient and provider experience,” said Dr. Jonathan Calkwood. Dr. Calkwood and Infusion Associates have built an innovative center of excellence care model for patients with multiple sclerosis and other neurological conditions which will be expanded across Vivo’s markets.
InTandem Capital Partners, a private equity investment firm with an exclusive focus in healthcare services, has been a strategic investor and capital partner to Vivo Infusion since 2021. In connection with the Infusion Associates acquisition, InTandem has raised nearly $150 million of additional equity capital from its limited partners to continue to support Vivo’s growth ambitions across the country during the remainder of 2024 and beyond. “We feel privileged to call the Vivo team our partners seeing first-hand their passionate focus on delivering great clinical outcomes and an industry-leading patient experience,” said Brad Coppens, Senior Partner at InTandem and member of the Board of Directors of Vivo Infusion. “We thank InTandem’s investors for their continued support of InTandem and Vivo Infusion.”
TripleTree served as the exclusive financial advisor to Infusion Associates for this transaction.
